Faculty

Assistant Professor of Urology Icahn School of Medicine at Mount Sinai New York, New York  

Dr. Dimple Chakravarty is an Assistant Professor in the Department of Urology at the Icahn School of Medicine at Mount Sinai. Before joining Mount Sinai, she served as a faculty member in the Genitourinary (GU) Oncology Department at UT MD Anderson Cancer Center and in the Department of Pathology at Weill Cornell Medicine.

Her training and research focus on genomics and cancer biology. She has extensive experience in functional genomics, proteomics, and RNA biology, including both long and small non-coding RNAs. Her work uses a range of biological systems, including cell lines, organoids, and animal models.

Dr. Chakravarty’s laboratory studies the genetic, immunological, and epigenetic factors that drive prostate cancer progression and aggressiveness. The team uses next-generation sequencing along with in vitro and in vivo models, including patient-derived xenografts, organoids, and cell-line systems, to identify and develop potential therapeutic strategies.

She led the first studies identifying the long non-coding RNA NEAT1 as a key driver of prostate cancer progression and is an inventor on the patent “NEAT1 as a prognostic marker and therapeutic target for prostate cancer.” Her lab also investigates androgen receptor signaling and immune modulation in prostate cancer. In addition, she serves as a principal investigator on a clinical trial evaluating the effectiveness of antiandrogen therapy combined with immunotherapy in molecularly stratified patients with high-risk prostate cancer.

Over the past 15 years, Dr. Chakravarty has mentored numerous undergraduate, graduate, and PhD trainees. She has also led multidisciplinary teams of clinicians, researchers, biostatisticians, and clinical fellows in the successful execution of several clinical trials.

 

Expertise: Prostate Cancer